The Latest Breaking News from MCK

As McKesson has outperformed the Dow Jones over the past year, analysts are bullish about the stock’s prospects.

Take a gander at these three stocks that are generating returns on invested capital (ROIC) that are among the best in the U.S. large-cap stock universe.

McKesson has underperformed relative to the S&P 500 Index over the past year, but Wall Street analysts remain bullish on its growth prospects.

With healthcare rapidly evolving through digital transformation, the demand for smarter, more efficient solutions is rising, and companies driving this shift are poised for significant upside. Therefore, investors might find opportunities in fundamentally strong healthcare IT stocks like Medtronic (MDT), McKesson Corp. (MCK), and Embecta (EMBC). Read more….

McKesson is expected to announce its third-quarter results next month, and analysts predict a single-digit growth in the company’s bottom-line figure.

Cencora has trailed the S&P 500 index over the past year, but analysts remain highly bullish about the stock’s prospects.

Although McKesson has underperformed relative to the broader Nasdaq Composite over the past year, Wall Street analysts maintain a bullish outlook on the stock’s prospects.

McKesson has exceeded the broader market's performance over the past year, and Wall Street analysts are highly positive about the stock's outlook.

The health-tech industry’s long-term growth is fueled by the growing need for cutting-edge technologies to address critical areas, as well as the demand for personalized medicine. Thus, it could be wise to invest in fundamentally solid health-tech stocks McKesson (MCK), Cardinal Health (CAH), and Zimmer Biomet (ZBH) poised for long-term…

With McKesson gearing up to release its second-quarter earnings next month, analysts expect a double-digit surge in earnings.

Despite Cardinal Health’s underperformance relative to the Nasdaq Composite over the past year, Wall Street analysts remain moderately optimistic about the stock’s prospects.